{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:19:25Z","timestamp":1787833165682,"version":"build-2784847793"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.blre.2026.101419","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:53:09Z","timestamp":1787755989000},"page":"101419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in differentiation syndrome in acute promyelocytic leukemia: From mechanisms to management"],"prefix":"10.1016","author":[{"given":"Shuang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2026.101419_bb0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101419_bb0010","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/JME-22-0141","article-title":"How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy","volume":"69","author":"Korsos","year":"2022","journal-title":"J Mol Endocrinol"},{"issue":"9","key":"10.1016\/j.blre.2026.101419_bb0015","article-title":"Acute promyelocytic leukemia, retinoic acid, and arsenic: a tale of dualities","volume":"14","author":"R\u00e9rolle","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.blre.2026.101419_bb0020","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202201027","article-title":"The p97\/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA","volume":"222","author":"Jaffray","year":"2023","journal-title":"J Cell Biol"},{"key":"10.1016\/j.blre.2026.101419_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.762653","article-title":"Early death and survival of patients with acute promyelocytic leukemia in ATRA plus arsenic era: a population-based study","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101419_bb0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/bloodadvances.2024014999","article-title":"Acute Promyelocytic leukemia Asian consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome","volume":"9","author":"Gill","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101419_bb0035","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s10637-025-01556-1","article-title":"Understanding the differentiation syndrome in acute promyelocytic leukemia: a comprehensive updated review","volume":"43","author":"Damaj","year":"2025","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.blre.2026.101419_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2017.09.001","article-title":"The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia","volume":"32","author":"Jillella","year":"2018","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2026.101419_bb0045","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.053","article-title":"Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic acid era","volume":"3","author":"Pagoni","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"7","key":"10.1016\/j.blre.2026.101419_bb0050","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.leukres.2013.04.011","article-title":"Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia","volume":"37","author":"Leblebjian","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101419_bb0055","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00277-020-04245-6","article-title":"Japan adult leukemia study group. Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia","volume":"99","author":"Minamiguchi","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101419_bb0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101419_bb0065","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1007\/s00277-024-05776-y","article-title":"Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide","volume":"103","author":"Gao","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101419_bb0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-024-01074-y","article-title":"Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia","volume":"14","author":"Wu","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101419_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-031-62731-6_14","article-title":"Function of PML-RARA in acute Promyelocytic leukemia","volume":"1459","author":"Testa","year":"2024","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.blre.2026.101419_bb0080","article-title":"The clinical characteristics and implications of acute kidney injury during induction therapy for acute promyelocytic leukemia","volume":"16","author":"Shen","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2026.101419_bb0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41419-025-08109-7","article-title":"Anti-inflammatory 25(OH)D(3), a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia","volume":"16","author":"Jambrovics","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.blre.2026.101419_bb0090","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.leukres.2005.01.005","article-title":"Induction of CXC and CC chemokines by all-trans retinoic acid in acute promyelocytic leukemia cells","volume":"29","author":"Shibakura","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101419_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0609.1999.tb01844.x","article-title":"In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells","volume":"63","author":"Hsu","year":"1999","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2026.101419_bb0100","first-page":"1639","article-title":"Effect of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells","volume":"116","author":"Jiang","year":"2003","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"10.1016\/j.blre.2026.101419_bb0105","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00277-017-2970-5","article-title":"Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1\u03b2","volume":"96","author":"Dunoyer-Geindre","year":"2017","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.blre.2026.101419_bb0110","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3324\/haematol.10607","article-title":"Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia","volume":"92","author":"Cunha De Santis","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101419_bb0115","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/bjh.19763","article-title":"Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia","volume":"205","author":"Yanada","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101419_bb0120","article-title":"Analysis of risk factors for differentiation syndrome in patients with acute promyelocytic leukemia","volume":"104","author":"Zhang","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2026.101419_bb0125","article-title":"Role of prophylactic steroids in differentiation syndrome","volume":"14","author":"Sultana","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.blre.2026.101419_bb0130","article-title":"Fatal differentiation syndrome complicating acute Promyelocytic leukemia treatment: a case report","volume":"16","author":"Khizer","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.blre.2026.101419_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08325.x","article-title":"Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia","volume":"151","author":"Luesink","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101419_bb0140","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.3390\/cancers15194767","article-title":"Differentiation syndrome in acute leukemia: APL and beyond","volume":"15","author":"Woods","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101419_bb0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/17843286.2025.2606872","article-title":"Acute promyelocytic leukemia complicated by osteofascial compartment syndrome","volume":"81","author":"Li","year":"2026","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.blre.2026.101419_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.10.003","article-title":"In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome","volume":"63","author":"Kojima","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101419_bb0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \u201cretinoic acid syndrome\u201d in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2026.101419_bb0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101419_bb0165","article-title":"Acute Promyelocytic leukemia with long and short isoforms of PML::RARA fusion transcripts complicated by abdominal distension and acute edematous pancreatitis during induction treatment: a case report","volume":"16","author":"Chu","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.blre.2026.101419_bb0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.14740\/jh904","article-title":"Acute respiratory distress syndrome in a patient with acute Promyelocytic leukemia: overlapping between differentiation syndrome and COVID-19","volume":"10","author":"Sui","year":"2021","journal-title":"J Hematol"},{"key":"10.1016\/j.blre.2026.101419_bb0175","article-title":"Differentiation syndrome-induced myopericarditis in the induction therapy of acute promyelocytic leukemia: a case report","volume":"7","author":"Shenoy","year":"2021","journal-title":"Cardiooncology"},{"key":"10.1016\/j.blre.2026.101419_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1095154","article-title":"Case report: high-risk acute promyelocytic leukemia and COVID-19-related myocarditis one patient, two cytokine storms","volume":"13","author":"Ghiaur","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0185","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2026.101419_bb0190","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/leu.2015.12","article-title":"European LeukemiaNet. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet","volume":"29","author":"Lengfelder","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101419_bb0195","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.3390\/jcm9103342","article-title":"Incidence of differentiation syndrome associated with treatment regimens in acute myeloid leukemia: a systematic review of the literature","volume":"9","author":"Gasparovic","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2026.101419_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107567","article-title":"Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide","volume":"145","author":"Cingelova","year":"2024","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101419_bb0205","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2024024008","article-title":"How I treat acute myeloid leukemia with differentiation therapy","volume":"145","author":"Issa","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101419_bb0210","doi-asserted-by":"crossref","first-page":"11935","DOI":"10.1038\/s41598-019-47937-4","article-title":"Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia","volume":"9","author":"Yoon","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2026.101419_bb0215","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"10.1016\/j.blre.2026.101419_bb0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12959-021-00294-7","article-title":"Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia","volume":"19","author":"Zhang","year":"2021","journal-title":"Thromb J"},{"key":"10.1016\/j.blre.2026.101419_bb0225","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12288-025-02036-5","article-title":"Predictors of differentiation syndrome in patients with acute Promyelocytic leukemia following induction therapy: a Meta-analysis","volume":"42","author":"Alghwyeen","year":"2026","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5","key":"10.1016\/j.blre.2026.101419_bb0230","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/j.clml.2026.01.016","article-title":"Real-world insights into acute promyelocytic leukemia (APL) in Egypt in the absence of arsenic trioxide (ATO): clinical characteristics, outcomes and risk factors for early mortality: a single center study","volume":"26","author":"Shaaban","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101419_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10499-2","article-title":"Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia","volume":"23","author":"Wen","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2026.101419_bb0240","article-title":"Influence of white blood cell count trajectories on the risk of differentiation syndrome during induction therapy with all-trans-retinoic acid and arsenic trioxide in pediatric acute promyelocytic leukemia","volume":"13","author":"Fu","year":"2025","journal-title":"Front Pediatr"},{"key":"10.1016\/j.blre.2026.101419_bb0245","first-page":"62","article-title":"Analysis of influencing factors and establishment of nomogram model of differentiation syndrome in patients with acute promyelocytic leukemia","volume":"33","author":"Yao","year":"2025","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.blre.2026.101419_bb0250","first-page":"183","article-title":"Study on clinical features of early death in older patients with acute promyelocytic leukemia","volume":"104","author":"Zhao","year":"2025","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101419_bb0255","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.leukres.2009.09.017","article-title":"High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia","volume":"34","author":"Jeddi","year":"2010","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.blre.2026.101419_bb0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2011-07-369595","article-title":"Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols","volume":"119","author":"Breccia","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101419_bb0265","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ejh.13346","article-title":"Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA protocols","volume":"104","author":"Sobas","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2026.101419_bb0270","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cyto.b.22252","article-title":"Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia","volume":"110","author":"Saraiva","year":"2026","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.blre.2026.101419_bb0275","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/cas.70328","article-title":"Frontline ATRA-ATO therapy for acute Promyelocytic leukemia in Japan: results from the prospective multicenter FBMTG-APL2017 trial","volume":"117","author":"Takase","year":"2026","journal-title":"Cancer Sci"},{"key":"10.1016\/j.blre.2026.101419_bb0280","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12672-024-01241-4","article-title":"Clinical characteristics and analysis of related factors associated with early death in newly diagnosed patients with acute promyelocytic leukemia","volume":"15","author":"Wang","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0285","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.70211","article-title":"Chinese children\u2019s leukemia group. Risk factors for DIC in paediatric APL: insights from the CCLG-APL 2016 study","volume":"208","author":"Xu","year":"2026","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101419_bb0290","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00277-026-06839-y","article-title":"Risk factors for early mortality (within 6 weeks of diagnosis) in Chinese children with acute leukemia: a single-center retrospective cohort study","volume":"105","author":"Du","year":"2026","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101419_bb0295","author":"PETHEMA APL2017 protocol [internet]"},{"key":"10.1016\/j.blre.2026.101419_bb0300","author":"NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 2.2026 [Internet]"},{"issue":"1","key":"10.1016\/j.blre.2026.101419_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35662","article-title":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia","volume":"131","author":"Jen","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2026.101419_bb0310","first-page":"57","article-title":"Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin","volume":"4","author":"Lo-Coco","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"10.1016\/j.blre.2026.101419_bb0315","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101419_bb0320","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0325","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3892\/mco.2021.2274","article-title":"Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk","volume":"14","author":"Wen","year":"2021","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2026.101419_bb0330","first-page":"227","article-title":"Influence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment","volume":"9","author":"Xu","year":"2018","journal-title":"Biomed Rep"},{"key":"10.1016\/j.blre.2026.101419_bb0335","series-title":"Acute promyelocytic leukaemia standard risk (chemotherapy free) induction [internet]","author":"eviQ Cancer treatments online","year":"2023"},{"key":"10.1016\/j.blre.2026.101419_bb0340","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute Promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.blre.2026.101419_bb0345","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO-25-00535","article-title":"Arsenic trioxide and all-trans retinoic acid combination therapy for the treatment of high-risk acute Promyelocytic leukemia: results from the APOLLO trial","volume":"43","author":"Platzbecker","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0350","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1182\/blood-2025-5214","article-title":"Ruxolitinib combined with dexamethasone is a promising prophylaxis method for differentiation syndrome in acute promyelocytic leukemia (APL2022)","volume":"146","author":"Zhu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101419_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.871590","article-title":"Atypical rearrangements in APL-like acute myeloid Leukemias: molecular characterization and prognosis","volume":"12","author":"Guarnera","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0360","first-page":"546","article-title":"TTMV::RARA positive acute promyelocytic leukemia in a child","volume":"63","author":"Li","year":"2025","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"10","key":"10.1016\/j.blre.2026.101419_bb0365","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41408-021-00561-w","article-title":"Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants","volume":"11","author":"Cicconi","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2026.101419_bb0370","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.5858\/arpa.2013-0345-RS","article-title":"Acute Promyelocytic leukemia: a review and discussion of variant translocations","volume":"139","author":"Adams","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.blre.2026.101419_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.911745","article-title":"The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome","volume":"12","author":"LaBella","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101419_bb0380","first-page":"523","article-title":"Efficacy of combination of ATRA, ATO and anthracyclines induction therapy in patients with acute promyelocytic leukemia","volume":"38","author":"Ma","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"6","key":"10.1016\/j.blre.2026.101419_bb0385","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/leu.2008.59","article-title":"Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia","volume":"22","author":"Habib","year":"2008","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.blre.2026.101419_bb0390","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1182\/blood-2009-02-204834","article-title":"Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome","volume":"114","author":"Luesink","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101419_bb0395","article-title":"Acute promyelocytic leukemia and severe differentiation syndrome in pregnancy\u2014a management challenge","volume":"13","author":"Droc","year":"2023","journal-title":"Life (Basel)"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101419_bb0400","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood-2024-212418","article-title":"Comparing loop diuretic efficacy and safety in patients with acute myeloid leukemia and differentiation syndrome","volume":"144","author":"Nethagani","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101419_bb0405","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s13054-025-05743-7","article-title":"Early mortality in patients with acute promyelocytic leukemia: a systematic review and meta-analysis","volume":"29","author":"Chean","year":"2025","journal-title":"Crit Care"},{"key":"10.1016\/j.blre.2026.101419_bb0410","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1007\/s00277-025-06495-8","article-title":"Efficacy and safety analysis of different treatment regimens in newly diagnosed acute promyelocytic leukemia","volume":"104","author":"Zhang","year":"2025","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2026.101419_bb0415","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/sj.leu.2404272","article-title":"Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia","volume":"20","author":"Tsimberidou","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101419_bb0420","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1186\/s12885-020-07330-1","article-title":"Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome","volume":"20","author":"Yamamoto de Almeida","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2026.101419_bb0425","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101419_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/cells14231841","article-title":"Synergy in immunostimulatory and pro-differentiation effects of vitamin D analog and fludarabine in acute myeloid leukemias","volume":"14","author":"Haldar","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.blre.2026.101419_bb0435","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3390\/cancers12040968","article-title":"Acute Promyelocytic leukemia during pregnancy: a systematic review of the literature","volume":"12","author":"Santolaria","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.blre.2026.101419_bb0440","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00277-015-2372-5","article-title":"Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia","volume":"94","author":"Sanz","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101419_bb0445","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41375-018-0139-4","article-title":"Management of patients with acute promyelocytic leukemia","volume":"32","author":"Kayser","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101419_bb0450","article-title":"Arsenic trioxide therapy during pregnancy: ATO and its metabolites in maternal blood and amniotic fluid of acute Promyelocytic leukemia patients","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0455","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/15384047.2018.1529122","article-title":"New onset acute promyelocytic leukemia during pregnancy: report of 2 cases","volume":"20","author":"Li","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.blre.2026.101419_bb0460","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(25)00236-4","article-title":"China acute Leukaemia epidemiology; clinical and multi-omics data consortium. Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study","volume":"12","author":"Yin","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101419_bb0465","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/14737140.2025.2604165","article-title":"Pediatric acute myeloid leukemia in Uruguay: clinical outcomes and diagnostic challenges in a national cohort (2008-2024)","volume":"26","author":"Dapueto","year":"2026","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.blre.2026.101419_bb0470","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12098-023-04689-4","article-title":"Treatment of pediatric acute Promyelocytic leukemia with retinoic acid and arsenic trioxide along with chemotherapy","volume":"91","author":"Srinivasan","year":"2024","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.blre.2026.101419_bb0475","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-025-02353-1","article-title":"A multicenter single-arm clinical study of Chinese children\u2019s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol","volume":"10","author":"Chang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2026.101419_bb0480","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1007\/s00277-025-06528-2","article-title":"Clinical characteristics and outcome of pediatric patients with high-risk acute promyelocytic leukemia, with special focus on risk factors of early death","volume":"104","author":"Gao","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101419_bb0485","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2025.038","article-title":"Long-term persistence of dysplastic features in patients with acute Promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide","volume":"17","author":"Santinelli","year":"2025","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.blre.2026.101419_bb0490","series-title":"Acute promyelocytic leukemia in children","author":"Abla","year":"2020"},{"key":"10.1016\/j.blre.2026.101419_bb0495","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/10428194.2024.2445701","article-title":"Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia","volume":"66","author":"Avgerinou","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101419_bb0500","first-page":"27","article-title":"All-trans retinoic acid-induced ototoxicity during chemotherapy in pediatric acute Promyelocytic leukemia","volume":"8","author":"Lee","year":"2021","journal-title":"Children (Basel)"},{"issue":"1","key":"10.1016\/j.blre.2026.101419_bb0505","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cncr.27650","article-title":"Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia","volume":"119","author":"Zhang","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.blre.2026.101419_bb0510","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00432-019-03076-x","article-title":"Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide","volume":"146","author":"Jin","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0515","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jgo.2020.03.019","article-title":"Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force","volume":"11","author":"Klepin","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0520","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/leu.2017.178","article-title":"Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy","volume":"32","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2026.101419_bb0525","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2025.066","article-title":"Prevention of early death in very elderly acute Promyelocytic leukemia patients using lower induction doses of all-trans retinoic acid","volume":"17","author":"Dalgetty","year":"2025","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"14","key":"10.1016\/j.blre.2026.101419_bb0530","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.3390\/cancers15143637","article-title":"Management of Acute Promyelocytic Leukemia at extremes of age","volume":"15","author":"Kayser","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101419_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112423","article-title":"Transcriptional and metabolic dissection of ATRA-induced granulocytic differentiation in NB4 acute promyelocytic leukemia cells","volume":"9","author":"Albanesi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.blre.2026.101419_bb0540","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12308-020-00428-2","article-title":"Bronchoalveolar lavage fluid review in acute promyelocytic leukemia differentiation syndrome","volume":"14","author":"Seifert","year":"2021","journal-title":"J Hematop"},{"key":"10.1016\/j.blre.2026.101419_bb0545","first-page":"33","article-title":"Clinical analysis of children with high-risk acute promyelocytic leukemia","volume":"31","author":"Gao","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.blre.2026.101419_bb0550","first-page":"2387","article-title":"Effect of triple-induction regimen including all-trans retinoic acid, arsenic trioxide plus anthracyclines for adults with non-high-risk acute promyelocytic leukemia","volume":"101","author":"Ma","year":"2021","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.blre.2026.101419_bb0555","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/GO.20.00226","article-title":"Walking a tightrope: dosage modifications and treatment outcomes of all-trans-retinoic acid, arsenic trioxide, and Daunorubicin for high-risk acute Promyelocytic leukemia","volume":"6","author":"Danthala","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0560","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00277-023-05270-x","article-title":"Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia","volume":"102","author":"Luo","year":"2023","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.blre.2026.101419_bb0565","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.blre.2015.11.004","article-title":"Swallowing a bitter pill\u2013oral arsenic trioxide for acute promyelocytic leukemia","volume":"30","author":"Torka","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101419_bb0570","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1186\/s13063-024-08664-y","article-title":"Induction treatments with and without addition of one dose anthracycline to all-trans retinoid acid and arsenic in pediatric non-high-risk acute promyelocytic leukemia: study protocol for a randomized controlled trial","volume":"25","author":"Fan","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.blre.2026.101419_bb0575","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41375-020-0892-z","article-title":"Study Alliance leukemia (SAL). A proof of concept phase I\/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory\/relapsed AML patients not eligible for intensive therapy","volume":"35","author":"Wass","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2026.101419_bb0580","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1200\/OP.20.00395","article-title":"Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute Promyelocytic leukemia","volume":"17","author":"Jillella","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.blre.2026.101419_bb0585","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/17407745231206465","article-title":"Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimen","volume":"21","author":"Backer","year":"2024","journal-title":"Clin Trials"},{"key":"10.1016\/j.blre.2026.101419_bb0590","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/10428194.2021.1894651","article-title":"Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?","volume":"62","author":"Dhakal","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101419_bb0595","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/CCO.0000000000001171","article-title":"Curative strategies for high-risk acute promyelocytic leukemia","volume":"37","author":"Chin","year":"2025","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.blre.2026.101419_bb0600","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27041775","article-title":"Differentiation syndrome in acute myeloid leukemia: molecular mechanisms, clinical spectrum, and emerging therapeutic paradigms","volume":"27","author":"Mansour","year":"2026","journal-title":"Int J Mol Sci"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:37:44Z","timestamp":1787830664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":120,"alternative-id":["S0268960X26000585"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101419","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in differentiation syndrome in acute promyelocytic leukemia: From mechanisms to management","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101419"}}